Briacell Therapeutics Corp Stock Price, News & Analysis

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) announced that all resolutions at the Annual and Special Meeting of Shareholders held on January 18, 2022, were approved. This includes the election of directors, setting the number of directors at seven, re-appointment of auditors MNP LLP, approval of the stock option plan, and an amendment to create a new class of subordinate voting shares. The voting results showed strong support, with director nominees receiving over 97% approval. Detailed voting results are filed on SEDAR.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) announced that its common shares will start trading on the Toronto Stock Exchange (TSX) on December 31, 2021. Concurrently, the shares will be de-listed from the TSX Venture Exchange. The normal-course issuer bid (NCIB) will continue under the new trading venue. The average daily trading volume prior to the NCIB was 15,073 shares, with a daily purchase limit of 3,768 shares on the TSX. BriaCell focuses on targeted immunotherapies for advanced breast cancer and other malignancies.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) announces insider intentions to acquire approximately 1.59 million common shares, representing 10% of the company's outstanding shares, starting January 31, 2022. Concurrently, the corporate buyback program continues, with 501,703 shares and 143,236 warrants repurchased to date. The company has raised $5.1 million from warrant exercises since November 1, 2021. With a cash balance of $55.5 million and no debt, BriaCell is well-positioned to pursue its cancer immunotherapy growth plans while enhancing shareholder value through these strategies.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) presented clinical results for its immunotherapy candidate Bria-IMT™ at the 2021 San Antonio Breast Cancer Symposium. The analysis included data from 34 advanced breast cancer patients treated with Bria-IMT™, with a focus on safety and efficacy. Key findings highlighted a disease control rate of 25% and 33% for monotherapy and combination studies, respectively. Notably, complete tumor reductions were observed in patients with HLA matches and Grade I/II tumors, suggesting potential targeted treatment efficacy.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has announced that the Mary Crowley Cancer Research Center in Dallas, Texas, is now screening advanced breast cancer patients for a Phase I/IIa trial combining BriaCell's lead candidate, Bria-IMT™, with Incyte's checkpoint inhibitors. Dr. Minal Barve will act as Principal Investigator. Additional sites in California and Kansas are also enrolling patients. This study aims to evaluate treatment effectiveness, with previous results showing an average survival of 12 months, significantly better than historical comparisons.

BriaCell Therapeutics Corp. (BCTX, BCTXW) has successfully repurchased 202,425 common shares and 70,246 warrants as part of its buyback program, aimed at enhancing shareholder value. The company is authorized to buy back up to 1,341,515 common shares and 411,962 warrants over the next 12 months. With a cash balance of US$57.3 million, BriaCell is well-positioned to advance its cancer immunotherapy strategies while executing this buyback. Additionally, Dr. William V. Williams, the CEO, will present at various upcoming conferences, underscoring the company's commitment to growth.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) announces the addition of Suzanne Ostrand-Rosenberg, Ph.D. to its Scientific Advisory Board. Dr. Ostrand-Rosenberg boasts over 40 years of experience in cancer immunology and has contributed significantly to the understanding of the immune response to cancer. Her notable research includes work on CD4+ T-helper lymphocytes and myeloid-derived suppressor cells. The collaboration aims to enhance BriaCell's pipeline of immunotherapies, particularly for advanced breast cancer.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has appointed Dr. Jane Gross to its Board of Directors. With over 30 years of biotech experience, Dr. Gross has held significant roles at various companies, emphasizing her expertise in cancer therapeutics. The Board hopes to leverage her insights to advance BriaCell's immunotherapy pipeline. Additionally, the company granted stock options to Dr. Gross and its Scientific Advisory Board. BriaCell also announced a contract with North Equities Corp. for marketing and investor engagement purposes, costing CAD$105,000.

BriaCell Therapeutics Corp. (BCTX, BCTXW) recognizes October as Breast Cancer Awareness Month, highlighting the ongoing need for effective breast cancer treatments. The company, with $57 million cash as of July 31, 2021, continues its targeted immunotherapy program, achieving a notable 12-month overall survival benefit in trials and resolving a severe tumor in a patient. Additionally, BriaCell has initiated a securities buyback program to enhance shareholder value. The company emphasizes its commitment to treating patients beyond mere statistics.